Dosing characteristics of oral treprostinil in real-world clinical practice

Por Balasubramanian, Vijay P., Messick, Chad R., Broderick, Meredith, Nelsen, Andrew C.
Publicado no Pulm Circ (2018)

Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension

Por Chen, Hubert, Rosenzweig, Erika B, Gotzkowsky, S Karl, Arneson, Carl, Nelsen, Andrew C, Bourge, Robert C
Publicado em 2013

Implantable system for treprostinil: a real-world patient experience study

Por Shapiro, Shelley, Bourge, Robert C., Pozella, Patti, Harris, David F., Borg, Erick H., Nelsen, Andrew C.
Publicado no Pulm Circ (2020)

Correction to: Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study

Por Dean, Bonnie B., Saundankar, Vishal, Stafkey-Mailey, Dana, Anguiano, Rebekah H., Nelsen, Andrew C., Gordon, Kathryn, Classi, Peter
Publicado no Drugs Real World Outcomes (2020)

Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study

Por Dean, Bonnie B., Saundankar, Vishal, Stafkey-Mailey, Dana, Anguiano, Rebekah H., Nelsen, Andrew C., Gordon, Kathryn, Classi, Peter
Publicado no Drugs Real World Outcomes (2020)

Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies

Por Tonelli, Adriano R., Sahay, Sandeep, Gordon, Kathryn W., Edwards, Lisa D., Allmon, Andrew G., Broderick, Meredith, Nelsen, Andrew C.
Publicado no Pulm Circ (2020)

Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms

Por Mathai, Stephen C., Hemnes, Anna Ryan, Manaker, Scott, Anguiano, Rebekah H., Dean, Bonnie B., Saundankar, Vishal, Classi, Peter, Nelsen, Andrew C., Gordon, Kathryn, Ventetuolo, Corey E.
Publicado no Ann Am Thorac Soc (2019)

Bronchodilation induced by PGE(2) is impaired in Group III pulmonary hypertension

Por Ozen, Gulsev, Benyahia, Chabha, Mani, Salma, Boukais, Kamel, Silverstein, Adam M., Bayles, Richard, Nelsen, Andrew C., Castier, Yves, Danel, Claire, Mal, Hervé, Clapp, Lucie H., Longrois, Dan, Norel, Xavier
Publicado no Br J Pharmacol (2019)

The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in African Americans

Por Roberts, Patrick J., Rollins, Kristan D., Kashuba, Angela D. M., Paine, Mary F., Nelsen, Andrew C., Williams, Eric E., Moran, Cassandra, Lamba, Jatinder K, Schuetz, Erin G., Hawke, Roy L.
Publicado em 2008

Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life

Por DuBrock, Hilary M., Nathan, Steven D., Reeve, Bryce B., Kolaitis, Nicholas A., Mathai, Stephen C., Classi, Peter M., Nelsen, Andrew C., Olayinka-Amao, Bimpe, Norcross, Lindsey N., Martin, Susan A.
Publicado no Pulm Circ (2021)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension

Por Bourge, Robert C, Tapson, Victor F, Safdar, Zeenat, Benza, Raymond L, Channick, Richard N, Rosenzweig, Erika B, Shapiro, Shelley, White, Richard James, McSwain, Christopher Shane, Gotzkowsky, Stephen Karl, Nelsen, Andrew C, Rubin, Lewis J
Publicado em 2013